The Beltway-based biopharma disputed the FDA’s conclusions regarding the data provided in its supplemental application for ...
A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, ...
While venture capital funding dipped to its six-year low in 2025, it nevertheless remained above pre-pandemic levels for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback